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With reference to the article published under the title “Pharmacologic agents for smoking 
cessation: A clinical review”,1 we would like to add some information related to smoking 
cessation therapy among pregnant females. In that article, in the nicotine replacement 
therapy section, pregnancy has been considered as a contraindication to the use of trans-
dermal patches, gum, lozenges, nasal sprays, and oral inhalers containing nicotine.
It is well-established that maternal smoking during pregnancy causes significant 
fetal morbidity but the role of nicotine replacement therapy (NRT) has not been clear 
until now. The greatest risk to an unborn baby’s health from smoking is posed by 
carbon monoxide, which can cause fetal hypoxia. Therefore, although using nicotine 
replacement therapy is not ideal for the baby, the risks of nicotine replacement therapy 
far outweigh the risks of continuing to smoke.2
Although there is no comparison of the benefits and risks associated with smoking 
or nicotine replacement therapy in patients, pregnancy is not a contraindication to its use 
in women. The US Food and Drug Administration has mentioned that nicotine can be 
given to pregnant women after consultation with a physician.3 The US guidelines mention 
the use of medication among pregnant smokers under the heading of effectiveness and 
safety. With regard to effectiveness, the US guidelines state that “based on the data, the 
panel did not make a recommendation regarding medication use during pregnancy”. 
With regard to safety, the guidelines mention that safety is not categorical. A designation 
of “safe” reflects a conclusion that the benefits of a drug outweigh its risks. Nicotine 
most likely does have adverse effects on the fetus during pregnancy. Although the use 
of nicotine replacement therapy exposes pregnant women to nicotine, smoking exposes 
them to nicotine plus numerous other chemicals that are injurious to the woman and 
fetus. These concerns must be considered in the context of inconclusive evidence that 
cessation medications boost abstinence rates in pregnant smokers.4
Even the American College of Obstetricians and Gynecologists mentions that “use 
of nicotine replacement therapy should be undertaken with close supervision and after 
careful consideration and discussion with the patient of the known risks of continued 
smoking and the possible risks of nicotine replacement therapy. If nicotine replacement 
is used, it should be with the clear resolve of the patient to quit smoking.”5 The US 
guidelines have been available since 2010. This letter aims to give the current status 
of nicotine replacement therapy in pregnant patients who wish to quit smoking.
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